Ethics approval and consent to participate: This trial was approved by regulatory and independent ethics committee at all participating sites and all patients had consented to participate in this trial.
Consent for publication: Not applicable.
Availability of data and materials: All data generated or analysed during this study are included in this published article and its supplementary information files.
Competing interests:
PJV: None.
EXC: Honoraria from Taiho, Bayer, and Eisai; institution funding for clinical trials from AZ, BMS, Merck, Zymeworks, and Novartis.
HXC: None.
ACL: Consulting role for Novartis.
KK: Clinical trial support from Novartis for upcoming capmatinib study
UNV: Research funding from Merck and Bristol Myers Squibb. Consulting fees and Honoraria from Merck, Bayer, BMS, AAA, Pfizer, Exelixis Inc.
SS: Research funding from Merck, Bristol Myers Squibb and Brooklyn ImmunoTherapeutics; Advisory Board: Merck and Boehringer Ingelheim.
VS: Grants or research support from Novartis, AbbVie, Agensys, Alfasigma, Altum, Amgen, Bayer, Berghealth, Blueprint Medicines, Boston Biomedical, Boston Pharmaceuticals, D3 Pharma, Dragonfly Therapeutics, Exelixis, Fujifilm, Idera Pharmaceuticals, Incyte, Inhibrx, Loxo Oncology, MedImmune, MultiVir, National Comprehensive Cancer Network, NCI-Cancer Therapy Evaluation Program, Novartis, Pfizer, PharmaMar, Takeda, The University of Texas MD Anderson Cancer Center, and Turning Point Therapeutics and advisory/board member role in Eli Lilly, Helsinn, Incyte, Relay Therapeutics, Loxo Oncology, MedImmune, Novartis, QED Therapeutics, and R-Pharma US.
DJR: Research funding and honoraria from Bayer and Roche, and travel funding and honoraria from Servier, Celgene, Taiho, Ipsen, and Astra Zeneca.
ARR: Consulting/advisory roles for Eli-Lilly, Medison, GSK, Merck, Bayer, and Adaptimmune; institutional research funding from Boerhinger-Ingelheim, Eli-Lilly, Boston Biomedicals, Deciphera, Karyopharm Therapeutics, Pfizer, Roche/Genentech, BMS, Medimmune, Amgen, GSK, Blueprint Medicines, Symphogen, Merck, AbbVie, Adaptimmune, and Iterion Therapeutics.
SPI: None.
SJH: None.
AS (Singh): None.
PLB: Consulting/advisory arrangements (uncompensated) with BristolMyersSquibb, Sanofi, Pfizer, Genentech/Roche, Amgen, Lilly, SeaGen, Merck, and Gilead; and institution receives clinical trials supports from Novartis, BristolMyersSquibb, Sanofi, Genentech/Roche, GlaxoSmithKline, Nektar Therapeutics, Merck, Lilly, Servier, PTC Therapeutics, SeaGen, Sanofi, Mersana, Amgen, Zymeworks, VelosBio, Bicara Therapeutics, AstraZeneca, and Pfizer.
ARH: Research and Consulting: Genentech Inc., Hoffmann La Roche Inc., Merck Serono S.A., GlaxoSmithKline Inc., Bristol-Myers Squibb Company, Novartis Pharmaceuticals Canada Inc., Boehringer Ingelheim International GmbH, AstraZeneca Pharmaceuticals LP, MedImmune LL and Pfizer Inc.
LW: None.
LAS: None.
LLS: Consulting/advisory arrangements with Merck, Pfizer, Celgene, AstraZeneca, Morphosys, Roche, Oncorus, Symphogen, Seattle Genetics, GlaxoSmithKline, Voronoi, Arvinas, Tessa, Navire, Relay, Rubius, Janpix, Daiichi Sanyko; stock ownership of Agios (spouse); leadership position in Treadwell Therapeutics (spouse); and institution receives clinical trials support from Novartis, Bristol-Myers Squibb, Pfizer, Boerhinger-Ingelheim, GlaxoSmithKline, Roche/Genentech, Karyopharm, AstraZeneca, Merck, Celgene, Astellas, Bayer, Abbvie, Amgen, Symphogen, Intensity Therapeutics, Mirati Therapeutics, Shattucks, Avid.
AS: Consulting/advisory arrangements within the last 5 years include: Merck, Bristol-Myers Squibb, Oncorus, Janssen. The institution receives clinical trial funding support from Novartis, Bristol-Myers Squibb, Symphogen AstraZeneca/Medimmune, Merck, Bayer, Surface Oncology, Northern Biologics, Janssen Oncology/Johnson & Johnson, Roche, Regeneron, Alkermes, Array Biopharma/Pfizer, GSK, Treadwell.
Funding: This study is supported by the NCI UM1 Grant CA186644. LLS holds a BMO Chair in Precision Cancer Genomics.
Authors' contributions:
PJV: analysis and interpretation of data; drafted the work and substantively revised it and approved the submitted version
EXC: analysis and interpretation of data; drafted the work; substantively revised and approved the submitted version
HXC: contributions to the conception; design of the work; interpretation of data; substantively revised and approved the submitted version
ACL: acquisition of data and approved the submitted version
KK: acquisition of data; substantively revised and approved the submitted version
UNV: acquisition of data and approved the submitted version
SS: acquisition of data and approved the submitted version
VS: acquisition of data; substantively revised and approved the submitted version
DJR: acquisition of data and approved the submitted version
ARR: acquisition of data; substantively revised and approved the submitted version
SPI: contributions to the conception; design of the work; interpretation of data; substantively revised and approved the submitted version
SJH: acquisition of data and approved the submitted version
AS (Singh): acquisition of data and approved the submitted version
PLB: acquisition of data; substantively revised and approved the submitted version
ARH: acquisition of data; substantively revised and approved the submitted version
LW: analysis and interpretation of data and approved the submitted version
LAS: acquisition of data and approved the submitted version
LLS: contributions to the conception; design of the work; acquisition, analysis, interpretation of data; drafted the work; substantively revised and approved the submitted version
AS: contributions to the conception; design of the work; acquisition, analysis, interpretation of data; drafted the work; substantively revised and approved the submitted version
Acknowledgements
We would like to thank the patients and their families for their participation, and all the investigators as well as the site staffs for their contributions to this study.